NICE technology appraisals of oncology treatments
NICE technology appraisals of oncology treatments
The appraisal of oncology treatments is a key activity conducted by the National Institute for Health and Care Excellence (NICE). As part of the Department of Health and Social Care in England, NICE provides evidence-based best practices to help get the best care to patients while ensuring value for the taxpayer.
The assessments and recommendations made by NICE have a profound impact on the accessibility of cancer treatments in England and Wales and often serve as a reference point for health technology assessment (HTA) bodies worldwide.
To help manufacturers (drug development sponsors) incorporate market access planning and navigate the complex landscape of HTA evaluation of innovative oncology treatments, Fortrea Market Access Consulting & HEOR has published a white paper that covers:
- An overview of NICE assessment methods
- Health economic modeling approaches
- The impact of NICE’s new severity modifier
- Implications for manufacturers
Through a review of 66 technology appraisals over two years, the authors highlight an important challenge faced by manufacturers with an oncology portfolio and discuss the need for careful market access planning to inform reimbursement and pricing strategies.
Get more on Fortrea's extensive experience and expertise in Oncology therapeutic development.
Related insights
More from our insights
Peer-reviewed journal articles featuring Fortrea oncologists published 2020-2024
Ressource herunterladen
San Francisco Bay Area biotech advances Phase I-II cancer immunotherapy trial with Fortrea
A San Francisco Bay Area biotech company approached Fortrea to manage a Phase I-II clinical trial evaluating a personalized, neoantigen-based vaccine.
Fallstudie herunterladen
Future directions in liquid biopsy technology
Recent technological advancements have dramatically improved the sensitivity of liquid biopsies, enabling earlier diagnosis, precise treatment selection and enhanced disease monitoring.
Weiterlesen
Guiding a biotech’s development of an immunotherapy cancer treatment with 'out-of-the-box' thinking
This case study delves into how Fortrea helped guide a sponsor's immunotherapy cancer treatment with out-of-the-box thinking.
Fallstudie herunterladen
Aligning core values to for a tripartite partnership and advance an oncology program
A partnership model matched the sponsor’s needs and enabled transparency in each interaction.
Fallstudie herunterladen
Our latest oncology publications
Our collaborative approach can result in co-authorship of peer-reviewed journal articles based on projects we’ve supported.
Ressource herunterladen
Beschleunigung der klinischen Entwicklung mithilfe von Studien mit einem Fokus auf Design, Diversität und Digitalisierung – in der Onkologie und in anderen Bereichen
Webinar ansehen
Clinical Development in the Precision Medicine Era
The era of precision medicine is reshaping oncology trials, offering unprecedented opportunities to tailor treatments to individual genetic profiles. This transformation brings challenges in trial design and execution, and companies must adapt their clinical development strategies to stay ahead.
Weiterlesen
It is never too early to start a strategic plan for oncology product development in the APAC region
In oncology, a goal-oriented, holistic strategic plan is crucial, even in the earliest phases of product development.
Weiterlesen
Eine wissenschaftliche Perspektive auf den Russisch-ukrainischen Krieg
Fortrea's efforts in continuing scientific research and clinical trials amidst the challenges posed by the Russia-Ukraine conflict.
Weiterlesen